Autoantibodies against tumor-related antigens: Incidence and biologic significance

Kobold, Sebastian; Lütkens, Tim; Cao, Yanran; Bokemeyer, Carsten; Atanackovic, Djordje

doi:10.1016/j.humimm.2010.03.015

Cited by 48 publications

(35 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies to tumor‐associated antigens (TAAs) have been extensively investigated for many years, but the biological significance of increased autoantibody levels in the circulation has yet to be clarified 19, 20, 21, 22, 23. While testing of autoantibodies to TAAs may have a potential benefit for early diagnosis of cancers, the association of these autoantibodies with prognosis of cancers has been shown to be inconsistent across studies.…”

Section: Discussionmentioning

confidence: 99%

Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer

et al. 2016

View full text Add to dashboard Cite

A recent study reported that circulating antibodies to CD25‐derived peptide antigens were significantly higher in patients with nonsmall cell lung cancer (NSCLC) than control subjects. The present study was, thus, undertaken to replicate the initial finding with different sample sets. An in‐house ELISA was applied to determine circulating IgG antibodies to linear peptide antigens derived from CD25. A total of 111 patients with NSCLC and 216 control subjects were recruited and divided into the discovery sample (51 vs 108) and the validation sample (60 vs 108) based on the time of sampling. Student's t test showed that circulating anti‐CD25 IgG levels were significantly higher in the patient group than the control group (t = 2.23, P = 0.027) and the validation sample replicated this finding (t = 3.31, P = 0.0012), generating a combined P value of 0.0004 (χ2 = 20.8, df = 4). Fisher's combining probability revealed that patients with stage IV NSCLC had a significant increase in anti‐CD25 IgG levels compared with control subjects (χ2 = 22.1, df = 4, P = 0.0002) but those with the other three stages did not. This study suggests that circulating anti‐CD25 IgG antibodies may have prognostic rather than early diagnostic values for lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Such proteins can stimulate cellular and humoral immune response, triggering specific autoantibody production [7,8]. The role of autoantibodies in cancer is 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 4 they are an epiphenomenon associated to inflammation and tumor progression [9]. Nevertheless, autoantibody responses to TAAs hold promising characteristics to consider them as blood biomarkers for cancer detection and they are currently being investigated as potential diagnostic tools in multiple cancer types.…”

Section: Introductionmentioning

confidence: 99%

Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer

Soler

Estévez

Villar-Vázquez

et al. 2016

Analytica Chimica Acta

View full text Add to dashboard Cite

Colorectal cancer is treatable and curable when detected at early stages. However there is a lack of less invasive and more specific screening and diagnosis methods which would facilitate its prompt identification. Blood circulating autoantibodies which are immediately produced by the immune system at tumor appearance have become valuable biomarkers for preclinical diagnosis of cancer. In this work, we present the rapid and label-free detection of colorectal cancer autoantibodies directly in blood serum or plasma using a recently developed nanoplasmonic biosensor. Our nanoplasmonic device offers sensitive and real-time quantification of autoantibodies with excellent selectivity and reproducibility, achieving limits of detection around 1 nM (150-160 ng·mL

show abstract

“…There is convincing evidence suggesting that circulating autoantibodies for cancer have diagnostic potential (1)(2)(3)(4)(5)(6). A successful test has been developed for early diagnosis of lung cancer (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Circulating antibodies to p16 protein-derived peptides in breast cancer

Chen

Huang

Zhang

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Overexpression of the p16 protein has been reported in breast cancer and may trigger the secretion of antibodies against itself. Circulating anti-p16 antibodies that were detected with a recombinant protein have been reported in breast cancer. The present study was designed to determine whether the levels of circulating IgG antibody to p16 protein-derived linear antigens are altered in breast cancer. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to determine circulating IgG against peptide antigens derived from the p16 protein in 152 female breast cancer patients and 160 healthy female subjects. The Student's t-test revealed that breast cancer patients exhibited significantly higher levels of anti-p16 IgG antibody compared to control subjects (t=2.02, P=0.045). In addition, ductal cancer appeared to be the main type contributing to the increased levels of circulating anti-p16 antibodies (t=2.08, P=0.038). Of all four stages of breast cancer, stage I was associated with the highest levels of IgG antibody (t=2.02, P=0.045) and receiver operating characteristic (ROC) analysis demonstrated that the area under the ROC curve was 0.74 (95% confidence interval: 0.65-083) and that the sensitivity against a specificity of 90% was 30.3%. Therefore, the levels of circulating IgG antibody to the p16 protein may be a potential biomarker for early diagnosis of breast cancer. IntroductionThere is convincing evidence suggesting that circulating autoantibodies for cancer have diagnostic potential (1-6). A successful test has been developed for early diagnosis of lung cancer (7-9). Breast cancer is a common malignant condition, mainly occurring in women, and the leading cause of cancer-related mortality among women, accounting for 23% of all female cancer cases worldwide (10). Although breast cancer is easy to diagnose by microscopic analysis of a sample, i.e., biopsy, early diagnosis of this malignancy is crucial. Circulating autoantibodies have been suggested to serve as biomarkers for the early diagnosis of breast cancer (11,12), but their sensitivity and specificity have not been satisfactory. Thus, it is crucial to identify a panel of useful tumor-associated antigens (TAAs) in order to develop antibody-based tests for the early diagnosis of breast cancer.The p16 protein is a cyclin-dependent kinase (CDK) inhibitor that has been found to be involved in the downregulation of the cell cycle through the inactivation of CDK (13-15). As this CDK inhibitor mainly plays a role in suppressing CDK4 and CDK6 activity and arresting cells during the G1 phase of the cell cycle (14,16), it is associated with the unrestrained growth that is the hallmark of cancer (17). A number of studies have suggested that the levels of circulating antibodies to the p16 protein are increased in patients with breast cancer (11,18,19). For example, Looi et al developed an in-house enzyme-linked immunoassay (ELISA) using recombinant p16 protein as antigens to detect anti-p16 IgG levels in the plasma of cancer patients (18) and ...

show abstract

Autoantibodies against tumor-related antigens: Incidence and biologic significance

Cited by 48 publications

References 102 publications

Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer

Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer

Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer

Circulating antibodies to p16 protein-derived peptides in breast cancer

Contact Info

Product

Resources

About